Evidence map›Paper›PMID 42465976›Full record

SynthesisPeerJ2026

Remimazolam

Jing Liu, Ke Ke Lu, Jiahang Chen, Weiwei Chen, Hongli Pang, Junjie Song, Ying Wang

Abstract readMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing Liu *The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Ke Ke Lu *The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Jiahang ChenThe First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Weiwei ChenThe First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Hongli PangThe First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Junjie SongThe First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Ying WangThe First Affiliated Hospital of Henan University, Kaifeng, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Procedural sedation is widely used to improve patient tolerability and satisfaction and minimize complications. Propofol is the most commonly used agent in procedural sedation, but its use is associated with a number of adverse effects. Remimazolam, which has a different mechanism of action compared to propofol, is a short-acting GABA-A receptor agonist. It is being increasingly used in procedural sedation. This meta-analysis aims to clarify the efficacy and safety of remimazolam versus propofol for procedural sedation in hysteroscopic surgery. We systematically searched studies published in PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials from the inception of the databases to February 28, 2025, for randomized controlled trials (RCTs) comparing the effect of remimazolam and propofol in procedural sedation for hysteroscopic surgery. Seven RCTs (

Indexed as

BenzodiazepinesHypnotics and SedativesHysteroscopyProcedural SedationPropofolFemaleHumansRandomized Controlled Trials as TopicBenzodiazepinesHypnotics and SedativesPropofolremimazolamAdverse effectsMeta-analysisPropofolRemimazolamSedation

Identifiers

PMID42465976
PMCPMC13374580

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.